Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2005
03/08/2005CA1341474C Purified igm
03/03/2005WO2005019819A1 Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
03/03/2005WO2005019478A1 Methods and compositions for modulating herpesviral replication and transcription activator
03/03/2005WO2005019474A2 Human autism susceptibility gene and uses thereof
03/03/2005WO2005019472A1 Method of detecting effect of controlling synoviolin activity
03/03/2005WO2005019471A2 Periostin-like factor: compositions and methods for making and using the same
03/03/2005WO2005019465A1 Sugar chain-cutting agent
03/03/2005WO2005019457A2 NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
03/03/2005WO2005019448A2 NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
03/03/2005WO2005019434A2 Serine protease inhibitors for treatment of bacterial infections
03/03/2005WO2005019429A2 Compositions and methods for enhancing phagocytosis or phagocyte activity
03/03/2005WO2005019427A2 Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals
03/03/2005WO2005019265A1 Improved method of purifying tfpi and tfpi analogs
03/03/2005WO2005019262A1 Purification of glucagon-like peptides
03/03/2005WO2005019261A1 Separation of polypeptides comprising a racemized amino acid
03/03/2005WO2005019260A1 INTERFERON-β COMPOSITE
03/03/2005WO2005019259A2 Variants of interleukin-1 receptor antagonist: compositions and uses thereof
03/03/2005WO2005019253A1 Plant-derived peptides harboring water-cleaning and antimicrobial activities
03/03/2005WO2005019251A2 Novel fungal proteins and nucleic acids encoding same
03/03/2005WO2005019250A1 Staphylococcus antibiotic peptides with a broad spectrum of action
03/03/2005WO2005019246A1 Coronavirus vaccines, therapeutics and diagnostics
03/03/2005WO2005019245A1 Heptadepsin
03/03/2005WO2005019244A1 Peptides which can bind to transforming growth factor beta 1 (tgf-beta1)
03/03/2005WO2005019241A2 Cationic antimicrobial peptides and compositions thereof
03/03/2005WO2005018743A1 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
03/03/2005WO2005018695A1 Sprayable wound debrider
03/03/2005WO2005018668A1 Method of inducing immune tolerance
03/03/2005WO2005018666A1 Polypeptide multimers having antiviral activity
03/03/2005WO2005018664A1 Method and cosmetic product containing beta-endorphin, which are intended to limit fatty tissue growth
03/03/2005WO2005018663A1 G-csf derivative for inducing immunological tolerance
03/03/2005WO2005018662A1 Use of polypeptides of the cupredoxin family in cancer therapy
03/03/2005WO2005018661A1 A method for treating cancer patients undergoing chemotherapy
03/03/2005WO2005018660A1 Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy
03/03/2005WO2005018659A2 Somatogenic therapy using a 20kda placental variant of growth hormone
03/03/2005WO2005018657A2 NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
03/03/2005WO2005018650A2 Anti-bacterial composition, especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent
03/03/2005WO2005018575A2 Estrogen receptor modulators and uses thereof
03/03/2005WO2005018542A2 Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
03/03/2005WO2005018535A2 Compositions and methods for treatment of severe acute respiratory syndrome (sars)
03/03/2005WO2005018330A1 Dosing regimen for flaviviridae therapy
03/03/2005WO2005005652A3 Methods for the identification of inhibitors of c4 long chain base hydroxylase activity in plants
03/03/2005WO2005000892A3 Glp-1 analog fusion plroteins
03/03/2005WO2004112830A3 Clostridial toxins for treating eye disorders
03/03/2005WO2004108071A3 Targeting polypeptides to the central nervous system
03/03/2005WO2004105793A3 Soluble clca-1 and antagonists to clca-1
03/03/2005WO2004104019A3 Anti-inflammatory/anti-microbial peptides for use in dialysis
03/03/2005WO2004101599A3 Antimicrobial peptide and methods of use thereof
03/03/2005WO2004093893A3 Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
03/03/2005WO2004092404A3 Inhibitors of acidic mammalian chitinase as asthma therapeutics
03/03/2005WO2004091552A3 Biodegradable glucosaminemuramyl peptides for apoptosis modulation
03/03/2005WO2004091476A3 Method of screening remedy for heart disease and medicinal composition for treating heart disease
03/03/2005WO2004089280A3 Reversible pegylated drugs
03/03/2005WO2004087054A3 Methods for modulating gastric secretion using prokineticin receptor antagonists.
03/03/2005WO2004084859A3 Nasal calcitonin formulations containing chlorobutanol
03/03/2005WO2004080405A3 Igf-binding protein-derived peptide or small molecule
03/03/2005WO2004078925A8 Methods and compositions for treating and preventing neurodegenerative diseases
03/03/2005WO2004078920A3 Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (kca)
03/03/2005WO2004073640A3 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
03/03/2005WO2004072269A9 Bex4 nucleic acids, polypeptides, and method of using
03/03/2005WO2004072265A3 Methods for monitoring drug activities in vivo
03/03/2005WO2004072111A3 Novel therapeutic and diagnostic apoptotic inductors
03/03/2005WO2004071411A3 Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620
03/03/2005WO2004069182A3 Active immunization to generate antibodies to soluble a-beta
03/03/2005WO2004063213A3 Peptides which target tumor and endothelial cells, compositions and uses thereof
03/03/2005WO2004031731A3 Methods for controlling proliferation of cells
03/03/2005WO2004031350A3 Modulation of forkhead box o1a expression
03/03/2005WO2004029212A3 In vivo gene silencing by chemically modified and stable sirna
03/03/2005WO2004005489A3 Nucleic acids encoding sarcocystic neurona antigen and uses thereof
03/03/2005WO2003099315A8 A pharmaceutical composition comprising a retro-iverso isomer peptide
03/03/2005WO2003089418A8 Indane acetic acid derivatives and their use as pharmaceutical agents
03/03/2005WO2003080110A8 Topical pathogenic-tissue-destroying liquid
03/03/2005WO2003076567A8 Heterologous g-csf fusion proteins
03/03/2005WO2003075848A3 Inhibitors for use in hemostasis
03/03/2005WO2003045317A3 Therapeutic protein and treatments
03/03/2005WO2003029401A3 Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
03/03/2005WO2002062203A9 Compositions and methods for the therapy and diagnosis of breast cancer
03/03/2005US20050049404 Peptidyl-propyl cis/trans isomerase polypeptides for use as tool in identifying modulators for treatment of cell proliferative disorders; antimitotic agents
03/03/2005US20050049403 Immunoglobulin for use in diagnosis, prevention and treatment of autoimmune, immunological and inflammatory disorders; immunotherapy
03/03/2005US20050049234 Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents
03/03/2005US20050049220 Dosing regimen for Flaviviridae therapy
03/03/2005US20050049218 Kidney or liver fibrosis; using antagonist against the mitogenic vascular endothelial growth factors (zvegf3), such as a monoclonal antibody against zvegf3, receptor binding variants, or antisense agents; antagonist of zvegf3 inhibits cell proliferation
03/03/2005US20050049217 Stimulating the proliferation of kidney tubule epithelial cells in vivo using Zvegf4, a mitogenic multidomain protein with homology to the PDGF/VEGF family of growth factors; platelet-derived growth factor (PDGF); vascular endothelial growth factors (VEGF); renal failure
03/03/2005US20050049213 Method for preventing or reversing asthma and compositions useful therefor
03/03/2005US20050049212 Eating disorders, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, osteoarthritis, gallstones, cancers of the reproductive organs, and sleep apnea; drug screening; diagnosis and therapy; kits; regulates metabolism of triglycerides
03/03/2005US20050049211 Oligonucleotides for treating hyperproliferative diseases such as cancer, inflammatory, developmental or metabolic disorders
03/03/2005US20050049200 Administering a luteinizing hormone-releasing hormone antagonist (LH-RH) in an amount to suppress endogenous LH while maintaining follicle stimulating hormone (FSH) secretion at a natural level and estrogen development is not affected up to ovulation induction
03/03/2005US20050049199 Administration of a comparatively short regimen of luteinizing hormone (LH) starting at the beginning of the stimulatory phase, and followed by follicle stimulating hormone (FSH) administration in a controlled ovarian hyperstimulation (COH) treatment to enhance multiple folliculogenesis
03/03/2005US20050049198 Contacting a cardiac ryanodine receptor (RyR2) with a fragment of a dihydropyridine receptor (DHPR) polypeptide; ischemic heart disease, congestive heart failure, cardiac hypertrophy (calcium overload), dysrhythmia, or heart attack, cardiomyopathy
03/03/2005US20050049197 Induction of immune response against desired determinants
03/03/2005US20050049196 Indirect delivery of growth factors into the central nervous system
03/03/2005US20050049195 Methods and compositions for nerve regeneration
03/03/2005US20050049194 Use of ephrins and related molecules to regulate cellular proliferation
03/03/2005US20050049193 Leptin-related peptides
03/03/2005US20050049192 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/03/2005US20050049191 Administering TA1 peptide by infusion so as to continuously maintain an immune stimulating-effective amount of the peptide in the patient during a treatment period of at least about 6 hours
03/03/2005US20050049190 Cation conducting gabaa receptors and their use
03/03/2005US20050049189 Immunosuppressive protein for use in treatment and prevention of allergic, autoimmune, skin and respiratory disorders
03/03/2005US20050049186 Peptides mimicking the biological activity of steroid hormones and their uses
03/03/2005US20050049185 Gene encoding a multidrug-resistance human P-glycoprotein homologue on chromosome 7p15-2 and uses thereof
03/03/2005US20050049184 Blood treatment using antibodies which bind to non-glycosylated leptin transport factor and/or to enzymes responsible for reducing blood concentrations of the glycosylated factor
1 ... 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 ... 3163